15 results about "GERD" patented technology

An implantable apparatus for treating reflux disease in a human or animal mammal patient, the implantable apparatus being configured to be fixated to the stomach of the patient and comprising two or more implantable movement restriction device segments, wherein each implantable movement restriction device segment is provided with at least one assembly element that fits with at least one assembly element of another of said two or more implantable movement restriction device segment, so the two or more implantable movement restriction device segments by said assembly elements can be assembled into an implantable assembled movement restriction device.

An implantable device for the treatment of acid reflux disease has a body including an outer surface adapted to rest against a patient's fundus wall. The device, when implanted in the patient, fills a volume in the patient's abdomen in the cardia area and above the cardia of the patient, when standing. The body prevents the cardia from moving through the diaphragm opening into the thorax, thereby preventing reflux by keeping the abdominal pressure supporting the cardia sphincter muscle. The device may be affixed to stomach tissue. The device may also be invaginated or otherwise indirectly secured in position.

This disclosure relates to compositions and methods for treating gastroparesis using an effective amount of an SGLT1 inhibitor compound of Formula I or II, or a pharmaceutically acceptable salt thereof. The invention also encompasses the use of these compounds in treating related gastrointestinal disorders such as irritable bowel syndrome (IBS), non-ulcer dyspepsia, chronic intestinal pseudo-obstruction, functional dyspepsia, colonic pseudo-obstruction, duotienogastric reflux, gastroesophageal reflux disease (GERD), ileus inflammation, and heartburn. The SGLT1 inhibitor compounds act primarily in the intestinal lumen and can be administered in various oral dosage forms, including coated capsules, coated tablets, liquids, powders, and orally disintegrating tablets, with dosages ranging from about 0.1 mg / day to about 60 mg / day.

Abstract The present invention relates to a reflux disease treatment apparatus, comprising two or more movement restriction device segments adapted to form an implantable movement restriction device with an elongated shape that maintains cardia in the correct position. The movement restriction device has proximal and a distal end, wherein the distal end is adapted to stabilize and hold the proximal end. The invention further comprises a control device for controlling the stimulation device to stimulate the cardia sphincter. The distal end can be further adapted to treat obesity, for example by stretching the wall of the stomach or filling out a volume of the stomach. Abstract The present invention relates to a reflux disease treatment apparatus, comprising two or more movement restriction device segments adapted to form an implantable movement restriction device Mar with an elongated shape that maintains cardia in the correct position. The movement restriction device has proximal and a distal end, wherein the distal end is adapted to stabilize and hold the proximal end. The invention further comprises a control device for controlling the stimulation device to stimulate the cardia sphincter. The distal end can be further adapted to treat obesity, for example by stretching the wall of the stomach or filling out a volume of the stomach. 20 24 21 64 87 30 A ug 2 02 4 A b s t r a c t

The present application provides an herbal supplement and method for alleviation of symptoms of gastroesophageal reflux disease (GERD). The herbal supplement comprises two or more herbal components selected from the group consisting of atractloydes extract, dandelion root extract, noni extract, hesperidin extract and quebracho extract.

An apparatus for the treatment of acid reflux disease has an implantable movement restriction device adapted to be at least partly invaginated by a patient's stomach fundus wall. A substantial part of the outer surface of the movement restriction device is adapted to rest against the stomach wall without injuring the latter in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen. The movement restriction device has a size of at least 125 mm3 and a circumference of at least 15 mm.

A surgical method of treating reflux disease comprising the steps of dissecting an outside of a fundus of a stomach at least partially down on a posterior side of the outside of the fundus, dissecting an esophagus such that the esophagus is disconnected from surrounding tissue at least 3 cm in a cranial direction from an angle of His, connecting the fundus to the esophagus, and placing an implantable movement restriction device between the angle of His and a diaphragm, such that a lower esophageal sphincter is prevented from sliding through an esophageal hiatus.

The invention relates to an intraluminar method of treating a reflux disease in a patient by implanting a device comprising an movement restriction device that, when implanted in a patient, fills a volume in the patient's abdomen that is close to and at least partially above the patient's cardia when the patient is in a standing position. The invention further relates to a method of restoring the location of the cardia in a patient suffering from a reflux disease and to an instrument suitable to use with intraluminar method and / or restoration method. Also disclosed are instruments treating a patient suffering hiatal hernia and providing a movement restriction device to be invaginated in the stomach fundus wall.

A movement restriction composition for use in a method of treatment of reflux disease treatment by surgery, the movement restriction composition comprising 50% - 100% silicone or 50% - 100% polyurethane. A coronal plane of the patient divides the esophagus of the patient in an anterior half and a posterior half. The treatment by surgery comprises dissecting an area of the patient's stomach, affixing the stomach fundus wall to the lower part of the patient's esophagus by providing sutures or staples, creating a pouch in the stomach fundus wall, and placing and in-vaginating the movement restriction composition in the pouch by providing sutures or staples to the stomach fundus wall. The center of gravity of the movement restriction composition can be positioned dorsal to the coronal plane for preventing the cardia from sliding through the patient's diaphragm opening into the patient's thorax.

An implantable medical device for treating reflux disease in a human patient, the implantable medical device comprising a movement restriction device having an outer surface including a biocompatible material. The movement restriction device is adapted to be fully invaginated by the stomach fundus wall of the patient, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, thereby preventing the cardia from sliding through the patient's diaphragm opening into the patient's thorax. The implantable medical device further comprises a holding device adapted to be held by a surgical instrument, wherein the holding device is at least partly placed inside the outer wall of the implantable medical device.

The present invention relates to 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, diastereomer, enantiomer, isotope, pro-drug or metabolite or mixture thereof, or a pharmaceutical composition comprising said TT00, for use in prevention and / or treatment of pain, such as chronic and / or peripheral pain and / or pain related to arthritis, such as osteoarthritis, or for use in prevention and / or treatment of said pain combined with b) GERD or c) anxiety in animals, such as dogs, cats or horses.

The present disclosure relates to treatment of reflux disease of a human patient. More particularly, a device is disclosed, which is configured to be implanted in the body of the human to restrict movement of the cardia of the patient's stomach towards the diaphragm opening into the patient's thorax, and / or to prevent stomach contents from passing from the stomach into the esophagus.

A surgical method of treating reflux disease comprising the steps of dissecting the fundus at least partially down on the posterior side thereof; in the approximate direction towards bursa Omentalis, as well as away from the spleen. The method further comprising the steps of dissecting the esophagus such that the esophagus is disconnected from the surrounding tissue at least 3 cm in a cranial direction from the angle of his and connecting the fundus to the esophagus by placing at least two posterior single sutures in a posterior suture line, or a posterior continuous suture line, connecting the fundus to the esophagus, on the sinister-posterior side of the esophagus, and placing at least two anterior sutures, in an anterior suture line, or an anterior continuous suture line, connecting the fundus to the esophagus, on the sinister-anterior side of the esophagus. The method further comprises placing an implantable movement restriction device between the angle of His and the diaphragm, such that the lower esophageal sphincter is prevented from sliding through the esophageal hiatus.

A method for affixing a fundus portion of the stomach of a human patient to the patient's esophagus is disclosed. The method comprises folding the fundus portion towards the esophagus such that the fundus portion rests against the esophagus, from the angle of His and upwards along the esophagus, and affixing the fundus portion to the esophagus by means of fasteners arranged along a first line and a second line. The first line and the second line extend along the esophagus and are arranged such that a distance between the first line and the second line increases with an increasing distance from the angle of His. The method can be used for invaginating a movement restriction device by the fundus, a position between the diaphragm and the cardiac sphincter to hinder the cardia from sliding through the diaphragm opening into the patient's thorax.

An implantable medical device for treating reflux disease, the implantable medical device comprising a movement restriction device (110) configured to be fixated to the stomach wall for hindering movement of the lower esophageal sphincter relative to the thoracic diaphragm. The movement restriction device comprises central part (111e), and at least two outer parts (111a-d) configured to be connected to each other along a vertical plane. The at least two outer parts are configured to be connected to the central part for forming at least a portion of a functional movement restriction device. The central part comprises at least one horizontally extending rim (151h1-4) and the central part has a contacting surface configured to contact at least one surface of the at least two outer parts, and wherein a portion of the horizontally extending rim is wedge-shaped with an angle in the range 20° - 60°.